Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biofrontera ( (BFRI) ) has issued an announcement.
On August 11, 2025, Biofrontera Inc. announced the appointment of George Jones as Chief Commercial Officer, effective August 25, 2025. Jones, with over 25 years of experience in the pharmaceutical and biotech sectors, will oversee the company’s commercial functions. This appointment comes as Biofrontera strengthens its management following the acquisition of all rights and assets related to Ameluz® and RhodoLED® for the U.S. market from Biofrontera AG. The acquisition is expected to bring the company closer to cash break-even by reducing royalty payments. Jones’ extensive experience in commercial leadership is anticipated to accelerate Biofrontera’s growth and enhance its market access strategies.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall stock score reflects significant financial challenges despite technical momentum. The company’s attempts to improve profitability and strategic acquisitions are overshadowed by high leverage, cash flow issues, and Nasdaq compliance risks.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of actinic keratosis (AK), pre-cancerous skin lesions which may progress to invasive skin cancers. The company also conducts clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.
Average Trading Volume: 198,861
Technical Sentiment Signal: Hold
Current Market Cap: $9.6M
For a thorough assessment of BFRI stock, go to TipRanks’ Stock Analysis page.